Bristol-Myers Squibb Company (BMY) Shares Sold by Carroll Financial Associates Inc.

Carroll Financial Associates Inc. trimmed its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 9.8% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,120 shares of the biopharmaceutical company’s stock after selling 2,196 shares during the quarter. Carroll Financial Associates Inc.’s holdings in Bristol-Myers Squibb were worth $1,121,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Welch Investments LLC boosted its holdings in Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 79 shares in the last quarter. Crestwood Advisors Group LLC acquired a new position in Bristol-Myers Squibb in the first quarter valued at approximately $116,000. Blue Chip Partners Inc. boosted its holdings in Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 17 shares in the last quarter. Proficio Capital Partners LLC boosted its holdings in Bristol-Myers Squibb by 29.6% in the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 504 shares in the last quarter. Finally, American National Bank boosted its holdings in Bristol-Myers Squibb by 11.7% in the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 225 shares in the last quarter. 68.80% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently issued reports on BMY shares. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $65.00 price target (up from $62.00) on shares of Bristol-Myers Squibb in a report on Thursday. Jefferies Group LLC reaffirmed a “buy” rating and issued a $64.00 price target on shares of Bristol-Myers Squibb in a report on Monday, June 5th. Piper Jaffray Companies set a $60.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Thursday, July 27th. Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 price target for the company in a report on Monday, June 5th. Finally, BidaskClub downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, July 3rd. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average target price of $62.54.

ILLEGAL ACTIVITY NOTICE: “Bristol-Myers Squibb Company (BMY) Shares Sold by Carroll Financial Associates Inc.” was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/09/10/bristol-myers-squibb-company-bmy-shares-sold-by-carroll-financial-associates-inc.html.

In related news, Director Theodore R. Samuels II acquired 6,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, August 2nd. The stock was acquired at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the transaction, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The disclosure for this sale can be found here. Insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Company (NYSE BMY) traded down 0.35% during midday trading on Friday, hitting $62.62. The stock had a trading volume of 6,579,322 shares. The firm has a market cap of $102.69 billion, a PE ratio of 22.87 and a beta of 1.18. The stock has a 50-day moving average price of $57.53 and a 200 day moving average price of $55.70. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $63.47.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The business had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the previous year, the firm posted $0.69 EPS. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. On average, analysts predict that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply